| Biomarker ID | 842 |
| PMID | 22241677 |
| Year | 2012 |
| Biomarker | breast cancer antiestrogen resistance 1 (BCAR1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Significantly associated with Biochemical Relapse |
| Odds Ratio/Hazard Ratio/Relative Risk | Multivariate Analysis: HR: 0.577, (95% CI: 0.359–0.928) |
| Effect on Pathways | Pathways Include:- VEGF, hypoxia, and angiogenesis,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,Integrins in angiogenesis,Bacterial invasion of epithelial cells,Plasma membrane estrogen receptor signaling |
| Experiment | Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 121 patients with biochemical relapse and 121 without replase were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.02 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Biochemical recurrence, defined as two consecutive increases in serum PSA 0.2 ng/ml or greater. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | BCAR1 |